BSECompany Update2d ago · 5 Nov 2026, 12:36 pm
Onesource Specialty Pharma Limited has informed the Exchange about the Participation in Jefferies Global Healthcare Conference to be held from November 16, 2026 to November 19, 2026 in London.
Onesource Specialty Pharma Ltd · 544292
✦ AI Summary
Onesource Specialty Pharma Ltd has informed the exchange about its participation in the Jefferies Global Healthcare Conference to be held from November 16, 2026 to November 19, 2026 in London.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Onesource Specialty Pharma Ltd - 544292 - The Company Is Informing The Exchange About Participation In Jefferies Global Healthcare Conference.
Attachments (1)
📄pdf
Download →
e3835264-2b72-4980-a251-865d391e4f45.pdf
View document text
Corporate Office: Registered Office:
Star 1, Opp IIM Bangalore, Bilekahalli, Cyber One, Unit No. 902, Sector 30A,
Bannergha(cid:425)a Road, Bengaluru – Plot No - 4 & 6, Vashi,
560076, India Navi Mumbai - 400703, India
T: +91 80 6784 0738 T: +91 22 2789 2924
Date: November 05, 2026
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G,
Dalal Street, Mumbai- 400001 Bandra Kurla Complex, Bandra (E), Mumbai – 400 051
Scrip Code: 544292 Symbol: ONESOURCE
Dear Sir/ Madam,
Subject: Intimation of Participation in Jefferies Global Healthcare Conference, under Regulation 30 of SEBI (LODR)
Regulations, 2015
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish
to inform you that the representatives of OneSource Specialty Pharma Limited will be participating in Jefferies Global
Healthcare Conference, scheduled to be held from November 16, 2026 to November 19, 2026 in London.
During these interactions, the Company’s representatives will discuss publicly available information including the
business overview, strategy, industry trends and growth outlook as part of the regular investor engagement activities.
Please note that no unpublished price sensitive information (UPSI) is proposed to be shared thereat.
You are requested to kindly take the same on record.
For and on behalf of
OneSource Specialty Pharma Limited
Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635
OneSource Specialty Pharma Limited
Formerly Stelis Biopharma Limited
info@onesourcecdmo.com | www.onesourcecdmo.com CIN: L74140MH2007PLC432497